S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
This NASDAQ Stock Is The Amazon Of Medical Supply (Ad)
Stock market today: Wall Street leaps, nearly escapes its bear market after strong jobs report
What Should Investors Make of These 3 Dividend Cuts?
15 A.I. Trading Opportunities a Day (Ad)
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
CrowdStrike: Another Tech Stock to Buy on the Dip 
Free SMS Trade Alerts. Up to 15 opportunities a day. (Ad)
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
Salesforce: Time to Snap it Up as the Market Buys the Dip?
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

$0.90
+0.05 (+5.91%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.83
$0.90
50-Day Range
$0.72
$1.48
52-Week Range
$0.72
$2.12
Volume
126,746 shs
Average Volume
566,668 shs
Market Capitalization
$73.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Pieris Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
1.00mentions of Pieris Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$8,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

442nd out of 983 stocks

Pharmaceutical Preparations Industry

213th out of 486 stocks


PIRS stock logo

About Pieris Pharmaceuticals (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

This NASDAQ Stock Is The Amazon Of Medical Supply
This Little Known Company IS Quickly Becoming The Amazon Of Medical Supply. Learn More Now
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
See More Headlines

PIRS Price History

PIRS Company Calendar

Last Earnings
3/29/2023
Today
6/02/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PIRS
Employees
124
Year Founded
N/A

Profitability

Net Income
$-33,280,000.00
Net Margins
-245.45%
Pretax Margin
-245.45%

Debt

Sales & Book Value

Annual Sales
$25.90 million
Book Value
$0.19 per share

Miscellaneous

Free Float
76,032,000
Market Cap
$69.73 million
Optionable
Optionable
Beta
1.08

Key Executives

  • Stephen S. Yoder
    President, Chief Executive Officer & Director
  • Thomas Bures
    Senior VP, Chief Financial & Accounting Officer
  • Kayti Aviano
    Vice President-Clinical Operations
  • Hitto Kaufmann
    Chief Scientific Officer & Senior Vice President
  • Shane OlwillShane Olwill
    Chief Development Officer & Senior Vice President













PIRS Stock - Frequently Asked Questions

How have PIRS shares performed in 2023?

Pieris Pharmaceuticals' stock was trading at $1.04 on January 1st, 2023. Since then, PIRS shares have decreased by 18.3% and is now trading at $0.8501.
View the best growth stocks for 2023 here
.

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PIRS earnings forecast
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its quarterly earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The biotechnology company had revenue of $5.85 million for the quarter, compared to analysts' expectations of $6.51 million. Pieris Pharmaceuticals had a negative trailing twelve-month return on equity of 133.94% and a negative net margin of 245.45%.

What other stocks do shareholders of Pieris Pharmaceuticals own?
What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (1.63%), Platinum Investment Management Ltd. (1.31%), Acadian Asset Management LLC (0.85%), Renaissance Technologies LLC (0.52%), Candriam S.C.A. (0.47%) and Affinity Asset Advisors LLC (0.37%). Insiders that own company stock include Aquilo Capital Management, Llc, Christopher P Kiritsy, Shane Olwill and Tim Demuth.
View institutional ownership trends
.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $0.85.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $69.73 million and generates $25.90 million in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444.

This page (NASDAQ:PIRS) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -